Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
Vaccine
; 16(20): 1907-16, 1998 Dec.
Article
em En
| MEDLINE
| ID: mdl-9796042
ABSTRACT
Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular five-component vaccine, 42.4% for an acellular two-component vaccine, and 28.5%, for a licensed US whole cell vaccine, compared to placebo. Logistic regression analyses demonstrated statistically significant correlations between clinical protection and the presence of IgG antibodies against pertactin, fimbriae 2/3 and pertussis toxin in pre-exposure sera. Multicomponent pertussis vaccines of proven high efficacy in recent Swedish NIAID-sponsored efficacy trials induced higher antibody levels against pertactin and fimbriae 2/3 than less efficacious vaccines. Anti-pertactin, anti-fimbriae 2/3, and anti-PT may be used as surrogate markers of protection for multicomponent acellular and whole-cell vaccines against pertussis.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bordetella pertussis
/
Vacina contra Coqueluche
/
Vacina contra Difteria, Tétano e Coqueluche
/
Proteínas de Fímbrias
/
Anticorpos Antibacterianos
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Vaccine
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Suécia